Efficacy of Amikacin Combined with Piperacillin/Tazobactam Sodium in Elderly with Severe Drug-Resistant Pseudomonas aeruginosa Pneumonia
Efficacy of Amikacin Combined with Piperacillin/Tazobactam Sodium in Elderly with Severe Drug-Resistant Pseudomonas aeruginosa Pneumonia
Hongxiao Li1*, Xiying Wu2, Dengxiang Wu1 and Jiangqing Yu1
ABSTRACT
The purpose of this study was to demonstrate the effects of amikacin combined with piperacillin/tazobactam sodium (PPC/TS) in the therapy of severe resistant Pseudomonas aeruginosa (Pa) pneumonia in elderly individuals. The sample of 50 elderly patients with PA pneumonia were selected and assigned into control group (Ctrl group, n=25, PPC/TS treatment) and experimental group (Exp group, n=25, amikacin +PPC/TS treatment) according to the single and even numbers. The between-group differences in CURB-65 score, CPIS score, APACHE II score, SOFA score, infection-related indicators, and bacterial clearance were compared. The CURB-65, CPIS, APACHE II, and SOFA scores in both groups were greatly decreased after the treatment, and the scores in the Exp. group were inferior to those in the Ctrl group substantially (P<0.05). The levels of WBC, NEUT, PCT, CRP, IL-6, and HBP in both groups were decreased drastically, and the scores in the Exp. group were dramatically lower than those in the Ctrl group (P<0.05). The bacterial clearance rate in the Exp. group was 64%, which was notably superior to 28% in the Ctrl group (P<0.05). The combination of amikacin and PPC/TS can greatly enhance the disease severity in elderly patients with severe drug-resistant PA, control the in vivo inflammatory response, promote the recovery of patients, enhance the quality of life of patients, and enhance the prognosis of the disease, which can provide a reference for clinical application.
To share on other social networks, click on any share button. What are these?
